ESR2 and medulloblastoma: Concurrently, ERβ agonists affect the sensitivity of malignant pleural mesothelial cells to cisplatin toxicity21 and the inhibition of ERβ, increases DNA repair, which in turn contributes to developing cisplatin resistance in medulloblastoma cells22.